![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EUROPEAN COMMISSION EXPANDS INDICATION FOR PLAVIX (CLOPIDOGREL BISULFATE) OFFERING NEW OPTION FOR PATIENTS WITH MOST SEVERE TYPE OF HEART ATTACK
EUROPEAN COMMISSION EXPANDS INDICATION FOR PLAVIX (CLOPIDOGREL BISULFATE) OFFERING NEW OPTION FOR PATIENTS WITH MOST SEVERE TYPE OF HEART ATTACK
Sanofi-aventis and Bristol-Myers Squibb Company announced that the European Commission has granted a new indication for the antiplatelet agent PLAVIX (clopidogrel bisulfate) to include patients with ST-segment Elevation acute Myocardial Infarction (STEMI) who are eligible for thrombolytic therapy. Yahoo Finance (http://biz.yahoo.com/cnw/060907/e_sanofi_a_plavix_r.html?.v=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct